Merz+co. Gmbh & Co.

Merz Pharma Gmbh & Co Kgaa

Forest Laboratories Holdings Limited

Erhard Seiller

Eberhard Nurnberg

Mahendra G Dedhiya

Bernhard Hauptmeier

Michael Althaus

Niranjan Rao

Antonia Periclou

Wattanaporn Abramowitz

Hagen Kruger

Barbara Ellers-Lenz

Tanja Rosenberg

Rajiv Janjikhel

Stefan Ritsert

Bernd Kuhn

Yan Yang

Hagen Krüger

Anshu Goel

Hagen Krueger

Wattanporn Abramowitz

The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus.

Titration package for neramexane and its use in the treatment of an inner ear disorder

The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Twithin the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of T.

Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane

The present invention provides solid pharmaceutical compositions in dosage form containing an active ingredient or principle, preferably memantine, which exhibit an extended two-phase release profile and which are characterized by the presence of both a water-soluble and a water-insoluble salt of casein, preferably sodium and calcium caseinate, in the matrix thereof, in broad proportions and in a total amount between 5 and 98% by weight of the composition, and with a process for the production thereof.

Memantine-containing solid pharmaceutical dosage forms having an

The application discloses a process for the manufacture of mechanically-stable, readily-disintegratable tablets made of small preformed, preferably rounded, particles or pellets containing a high percentage of active ingredient in which--prior to compression--the particles are coated with an aqueous or aqueous/organic suspension containing water-soluble polyvinyl alcohol having an ester content of 19.4 to 6.7%, a disintegrant, and finely-divided cellulose, the remainder being excipients such as additional colloids, adjuvants, dyes, and/or flavors and the suspending liquid, and dried, the stable but readily-friable tablet product thus-produced, and a method of delivering an active ingredient by the employment of such a tablet for oral ingestion.

Mechanically-stable, readily-disintegratable tablets made of small

Growing community of inventors

Nidderau, Germany

Erhard Seiller